Title of article :
Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C
Author/Authors :
Xiaowen Su، نويسنده , , Leland J. Yee، نويسنده , , KyungAh Im، نويسنده , , Shannon L. Rhodes، نويسنده , , YongMing Tang، نويسنده , , Xiaomei Tong، نويسنده , , Charles Howell، نويسنده , , Darmendra Ramcharran، نويسنده , , Hugo R. Rosen، نويسنده , , Milton W. Taylor، نويسنده , , T. Jake Liang، نويسنده , , Huiying Yang and for the Virahep-C Study Group، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2008
Abstract :
Background/Aims
Interferon signaling pathway genes (IPGs) and interferon-stimulated genes (ISGs) are associated with the host response to hepatitis C virus (HCV) infection. We studied single nucleotide polymorphisms (SNPs) in IPGs and ISGs for their associations with response to pegylated interferon α-2a (Peg-IFN-α) plus ribavirin therapy in HCV genotype-1 infected patients.
Methods
A two-stage study design was used. First, out of 118 SNPs selected, 91 SNPs from 5 IPGs and 12 ISGs were genotyped in a cohort of 374 treatment-naı¨ve HCV patients and assessed for association with sustained virologic response (SVR). Next, 14 potentially functional SNPs from the OASL gene were studied in this cohort.
Results
Three OASL SNPs (rs3213545 and rs1169279 from stage I, and rs2859398 from stage II), were significantly associated with SVR [rs3213545: p = 0.03, RR = 1.27 (1.03–1.58); rs1169279: p = 0.02, RR = 1.32 (1.05–1.65) p = 0.02; rs2859398: p = 0.02, RR = 1.29 (1.04–1.61)] after adjusting for other covariates. Further analysis showed that these three SNPs independently associated with SVR. Additionally, a similar trend towards the associations of these three SNPs with SVR was observed in a smaller, independent HCV cohort consisting of subjects from a number of clinical practice settings.
Conclusions
Our study suggests that OASL variants are involved in the host response to IFN-based therapy in HCV patients.
Keywords :
pharmacogenetics , hepatitis C , Interferon therapy , Interferon signaling pathway genes , Interferon-stimulatedgenes , race , therapy , Interferon , genetics
Journal title :
Journal of Hepatology
Journal title :
Journal of Hepatology